Todd A. Alonzo, PhD

Professor of Research Population and Public Health Sciences

Group Statistician for Children's Oncology Group

Image of Todd A. Alonzo, PhD
Is this your profile? Click to edit

Overview

Todd Alonzo is a Professor of Research in the Department of Preventive Medicine, University of Southern California. He received his undergraduate degree at the California State Polytechnic University, San Luis Obispo, California in Statistics in 1994 and received both his MS and his PhD in Biostatistics in 1997 and 2000 from the University of Washington, Seattle. Dr. Alonzo’s main areas of research interest are the statistical methods for analysis of biomarkers and medical diagnostic and screening tests, clinical trials, and the design and analysis of pediatric acute myelogenous leukemia studies. He has published over 225 peer-reviewed articles.

Dr. Alonzo has been member of the Editorial Board for Biometrics, Pediatric Blood Cancer, and Biometrical Journal and has acted as a reviewer for 30 scientific journals. He is a member of several Data Safety and Monitoring Boards. Dr. Alonzo was the President of the International Biometric Society Western Northern America Region (WNAR) in 2009. He is a Fellow of the American Statistical Association.

Awards

  • Fellow, American Statistical Association, 2018
  • The International Society for Magnetic Resonance in Medicine: Outstanding Teacher Award, 2017
  • University of Washington: Senior Biostatistics Award, Department of Biostatistics, 2000
  • ENAR Biometrics Society Distinguished Student Paper Award, 1999
  • WNAR Biometrics Society Best Student Oral Presentation, 1999
  • NIH: Predoctoral Cardiovascular Biostatistics Training Grant, 1995

Publications

  • Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective study Pediatr Blood Cancer. 2024 Jul; 71(7):e31006. . View in PubMed
  • Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia Blood Adv. 2024 Jun 25; 8(12):3200-3213. . View in PubMed
  • Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G Oncologist. 2024 Jun 14. . View in PubMed
  • Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH Trial JCO Precis Oncol. 2024 Jun; 8:e2400103. . View in PubMed
  • Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial Oncologist. 2024 May 30. . View in PubMed
  • EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion bioRxiv. 2024 May 17. . View in PubMed
  • Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia Blood Adv. 2024 Apr 23; 8(8):2005-2017. . View in PubMed
  • Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial Cancers (Basel). 2024 Apr 09; 16(8). . View in PubMed
  • A new genomic framework to categorize pediatric acute myeloid leukemia Nat Genet. 2024 Feb; 56(2):281-293. . View in PubMed
  • CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children’s Oncology Group Haematologica. 2024 Feb 01. . View in PubMed
  • Prognostic Impact of Co-occurring Mutations in FLT3-ITD Pediatric Acute Myeloid Leukemia Blood Adv. 2024 Jan 31. . View in PubMed
  • Bayesian semiparametric model for sequential treatment decisions with informative timing Biostatistics. 2024 Jan 16. . View in PubMed
  • Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children’s Oncology Group Clin Cancer Res. 2024 Jan 10. . View in PubMed
  • Population-Based Data Linkage Describing Patterns of Cancer Clinical Trial Enrollment Among Children and Adolescents JCO Oncol Pract. 2024 Jan 09; OP2300325. . View in PubMed
  • Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia Cancer. 2024 03 15; 130(6):962-972. . View in PubMed
  • Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children’s Oncology Group report Front Cardiovasc Med. 2024; 11:1347547. . View in PubMed
  • Information fraction estimation: Strategies for a phase 3 non-inferiority maximum duration design with time to event outcome Pharm Stat. 2023 Nov-Dec; 22(6):1031-1045. . View in PubMed
  • Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children’s Oncology Group Proteomics Clin Appl. 2023 Nov; 17(6):e2200109. . View in PubMed
  • Reply to ZR. McCaw et al. J Clin Oncol. 2023 Sep 20; 41(27):4447. . View in PubMed
  • IL-10 and TNFa are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children’s oncology group report Pediatr Hematol Oncol. 2023 Mar; 40(2):147-158. . View in PubMed
  • Children’s Oncology Group’s 2023 blueprint for research: Myeloid neoplasms Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30584. . View in PubMed
  • Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children’s Oncology Group Pediatr Blood Cancer. 2023 05; 70(5):e30251. . View in PubMed
  • Comparison of design methods for a safety run-in phase of a phase II clinical trial Clin Trials. 2023 04; 20(2):181-191. . View in PubMed
  • CREBBP alterations are associated with a poor prognosis in de novo AML Blood. 2023 04 27; 141(17):2156-2159. . View in PubMed
  • Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363. . View in PubMed
  • Rationale and design of the Children’s Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy Front Cardiovasc Med. 2023; 10:1286241. . View in PubMed
  • Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis Blood Adv. 2023 10 10; 7(19):5941-5953. . View in PubMed
  • Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia Haematologica. 2023 08 01; 108(8):2044-2058. . View in PubMed
  • Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia J Clin Oncol. 2023 06 01; 41(16):2949-2962. . View in PubMed
  • SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia Blood Adv. 2023 06 13; 7(11):2538-2550. . View in PubMed
  • Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication Nat Commun. 2023 04 05; 14(1):1739. . View in PubMed
  • Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children’s Oncology Group Lancet Haematol. 2022 Sep; 9(9):e678-e688. . View in PubMed
  • Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival Cancers (Basel). 2022 Jan 26; 14(3). . View in PubMed
  • Safety and Acceptability of Three Ablation Treatments for High-Grade Cervical Precancer: Early Data From a Randomized Noninferiority Clinical Trial JCO Glob Oncol. 2022 12; 8:e2200112. . View in PubMed
  • Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients Contemp Clin Trials. 2022 09; 120:106849. . View in PubMed
  • Automated Ascertainment of Typhlitis From the Electronic Health Record JCO Clin Cancer Inform. 2022 09; 6:e2200081. . View in PubMed
  • A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials Leukemia. 2022 08; 36(8):2022-2031. . View in PubMed
  • Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance? Pediatr Blood Cancer. 2022 06; 69(6):e29613.. View in PubMed
  • Proteomics Clin Appl. 2022 03; 16(2):e2100072. . View in PubMed
  • Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children’s Oncology Group Pediatr Blood Cancer. 2022 01; 69(1):e29313. . View in PubMed
  • Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation J Clin Oncol. 2022 03 01; 40(7):772-783. . View in PubMed
  • Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children’s Oncology Group AAML1331 Trial JAMA Oncol. 2022 Jan 01; 8(1):79-87. . View in PubMed
  • CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group J Clin Oncol. 2022 01 20; 40(3):252-261. . View in PubMed
  • Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children’s Oncology Group Pediatric MATCH Trial J Clin Oncol. 2022 07 10; 40(20):2224-2234. . View in PubMed
  • Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial J Clin Oncol. 2022 07 10; 40(20):2235-2245. . View in PubMed
  • Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study Haematologica. 2022 10 01; 107(10):2329-2343. . View in PubMed
  • Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children’s Oncology Group Protocol AAML1031 J Clin Oncol. 2022 06 20; 40(18):2023-2035. . View in PubMed
  • Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia Blood Cancer Discov. 2022 05 05; 3(3):194-207. . View in PubMed
  • Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia Nat Commun. 2022 09 19; 13(1):5487. . View in PubMed
  • Comparison of the Transcriptomic Signatures in Pediatric and Adult CML Cancers (Basel). 2021 Dec 14; 13(24). . View in PubMed
  • Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia Clin Transl Oncol. 2021 Oct; 23(10):2141-2154. . View in PubMed
  • Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG Cancers (Basel). 2021 May 12; 13(10). . View in PubMed
  • Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children’s Oncology Group Pediatr Blood Cancer. 2021 12; 68(12):e29281. . View in PubMed
  • Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer JCO Clin Cancer Inform. 2021 08; 5:881-896. . View in PubMed
  • Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia Pediatr Blood Cancer. 2021 07; 68(7):e28946. . View in PubMed
  • High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial Blood. 2021 12 09; 138(23):2337-2346. . View in PubMed
  • Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia Blood Adv. 2021 05 11; 5(9):2350-2361. . View in PubMed
  • Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report Blood. 2021 02 25; 137(8):1050-1060. . View in PubMed
  • CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group Blood. 2021 09 30; 138(13):1137-1147. . View in PubMed
  • Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children’s Oncology Group Trial AAML0531 J Clin Oncol. 2021 10 01; 39(28):3149-3160. . View in PubMed
  • CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes Blood Adv. 2021 12 14; 5(23):4963-4968. . View in PubMed
  • The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia Haematologica. 2021 02 01; 106(2):630-634. . View in PubMed
  • Information fraction estimation based on the number of events within the standard treatment regimen Biom J. 2020 Dec; 62(8):1960-1972. . View in PubMed
  • Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador JCO Glob Oncol. 2020 10; 6:1519-1530. . View in PubMed
  • Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group Haematologica. 2020 07; 105(7):1879-1886. . View in PubMed
  • A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children’s Oncology Group AAML05P1 Study Biol Blood Marrow Transplant. 2020 04; 26(4):712-717. . View in PubMed
  • Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children’s Oncology Group Protocol AAML0431 Arch Pathol Lab Med. 2020 04; 144(4):466-472. . View in PubMed
  • The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador Prev Med. 2020 02; 131:105931. . View in PubMed
  • Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group Cytometry B Clin Cytom. 2020 01; 98(1):52-56. . View in PubMed
  • Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group J Clin Oncol. 2020 07 01; 38(19):2170-2177. . View in PubMed
  • Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia Blood. 2020 04 30; 135(18):1603-1606. . View in PubMed
  • Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study Clin Cancer Res. 2020 02 01; 26(3):726-737. . View in PubMed
  • Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children’s Oncology Group Blood Adv. 2020 12 08; 4(23):6000-6008. . View in PubMed
  • Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force Cancer. 2020 02 01; 126(3):593-601. . View in PubMed
  • Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children’s Oncology Group Clin Cancer Res. 2020 06 15; 26(12):2891-2897. . View in PubMed
  • Blood Adv. 2020 10 27; 4(20):5050-5061. . View in PubMed
  • Adaptive trial designs in diagnostic accuracy research Stat Med. 2020 02 28; 39(5):591-601. . View in PubMed
  • Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children’s Oncology Group J Clin Oncol. 2020 07 20; 38(21):2398-2406. . View in PubMed
  • Evaluation of two alternative ablation treatments for cervical pre-cancer against standard gas-based cryotherapy: a randomized non-inferiority study Int J Gynecol Cancer. 2019 May 03. . View in PubMed
  • Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions Nat Med. 2019 Mar; 25(3):530. . View in PubMed
  • Comparisons of New HIV Rapid Test Kit Performance AIDS Behav. 2019 Feb; 23(2):313-317. . View in PubMed
  • Evaluating the predictive value of measures of susceptibility to tobacco and alternative tobacco products Addict Behav. 2019 09; 96:50-55. . View in PubMed
  • Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia Leukemia. 2019 08; 33(8):1934-1943. . View in PubMed
  • Quality of life in pediatric acute myeloid leukemia: Report from the Children’s Oncology Group Cancer Med. 2019 08; 8(9):4454-4464. . View in PubMed
  • Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children’s Oncology Group acute myeloid leukemia trials Pediatr Blood Cancer. 2019 08; 66(8):e27700. . View in PubMed
  • Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children’s Oncology Group Study AAML0631 J Pediatr Hematol Oncol. 2019 01; 41(1):51-55. . View in PubMed
  • Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia Clin Cancer Res. 2019 08 15; 25(16):5038-5048. . View in PubMed
  • CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group JCO Precis Oncol. 2019; 3. . View in PubMed
  • ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial Blood Cancer J. 2019 05 21; 9(6):51. . View in PubMed
  • Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children’s Oncology Group JCO Precis Oncol. 2019; 3. . View in PubMed
  • The Children’s Oncology Group: Organizational Structure, Membership, and Institutional Characteristics J Pediatr Oncol Nurs. 2019 Jan/Feb; 36(1):24-34. . View in PubMed
  • Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group J Clin Oncol. 2019 01 01; 37(1):12-21. . View in PubMed
  • Erratum: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions Nat Med. 2018 Apr 10; 24(4):526. . View in PubMed
  • Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador Prev Med. 2018 09; 114:149-155. . View in PubMed
  • Estimation of the volume under the receiver-operating characteristic surface adjusting for non-ignorable verification bias Stat Methods Med Res. 2018 03; 27(3):715-739. . View in PubMed
  • Effects of Maintenance on Quality of Performance of Cryotherapy Devices for Treatment of Precancerous Cervical Lesions J Low Genit Tract Dis. 2018 01; 22(1):47-51. . View in PubMed
  • The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions Nat Med. 2018 01; 24(1):103-112. . View in PubMed
  • Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis J Low Genit Tract Dis. 2018 Jan; 22(1):27-30. . View in PubMed
  • Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group Blood. 2018 10 11; 132(15):1584-1592. . View in PubMed
  • Performance of cigarette susceptibility index among e-cigarette and hookah users Drug Alcohol Depend. 2018 02 01; 183:43-50. . View in PubMed
  • MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia J Clin Oncol. 2017 Dec 10; 35(35):3964-3977. . View in PubMed
  • Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children’s Oncology Group Pediatr Blood Cancer. 2017 Dec; 64(12). . View in PubMed
  • Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children’s Oncology Group report Oncotarget. 2017 Oct 27; 8(52):90037-90049. . View in PubMed
  • Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children’s Oncology Group Phase III Historically Controlled Trial AAML0631 J Clin Oncol. 2017 Sep 10; 35(26):3021-3029. . View in PubMed
  • CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531 J Clin Oncol. 2017 Aug 10; 35(23):2674-2682. . View in PubMed
  • Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group Clin Cancer Res. 2017 Jul 15; 23(14):3649-3656. . View in PubMed
  • Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531 Haematologica. 2017 12; 102(12):2058-2068. . View in PubMed
  • Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group Haematologica. 2017 09; 102(9):e340-e343. . View in PubMed
  • Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range J Clin Pharmacol. 2017 09; 57(9):1183-1193. . View in PubMed
  • Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report Blood. 2017 06 08; 129(23):3051-3058. . View in PubMed
  • Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial Blood. 2017 06 22; 129(25):3304-3313. . View in PubMed
  • Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia Br J Haematol. 2017 Jan; 176(1):86-91. . View in PubMed
  • Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531 Blood. 2017 08 17; 130(7):943-945. . View in PubMed
  • Inverse probability weighting estimation of the volume under the ROC surface in the presence of verification bias Biom J. 2016 Nov; 58(6):1338-1356. . View in PubMed
  • Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children’s oncology group Int J Cancer. 2016 Nov 01; 139(9):1930-5. . View in PubMed
  • Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children’s Oncology Group Clin Cancer Res. 2016 Apr 15; 22(8):1951-7. . View in PubMed
  • Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador J Low Genit Tract Dis. 2016 Apr; 20(2):145-50. . View in PubMed
  • CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531 J Clin Oncol. 2016 Mar 01; 34(7):747-55. . View in PubMed
  • miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children’s Oncology Group Pediatr Blood Cancer. 2016 12; 63(12):2096-2103. . View in PubMed
  • A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group Leukemia. 2016 10; 30(10):2077-2080. . View in PubMed
  • Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children’s Oncology Group report Cancer Med. 2016 09; 5(9):2412-6. . View in PubMed
  • A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children’s Oncology Group Leuk Lymphoma. 2016 07; 57(7):1567-74. . View in PubMed
  • CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML Blood. 2016 06 16; 127(24):3094-8. . View in PubMed
  • Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia Nat Genet. 2016 Jan; 48(1):101. . View in PubMed
  • Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AMLA Report from the Children’s Oncology Group. Front Genet. 2016; 7:139. . View in PubMed
  • Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group J Hematol Oncol. 2016 11 30; 9(1):133. . View in PubMed
  • Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia J Clin Oncol. 2016 05 01; 34(13):1537-43. . View in PubMed
  • Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy J Hematol Oncol. 2016 09 06; 9(1):82. . View in PubMed
  • Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children’s Oncology Group J Clin Oncol. 2016 11 01; 34(31):3766-3772. . View in PubMed
  • Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study Blood. 2016 06 30; 127(26):3424-30. . View in PubMed
  • Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse Cancer Res. 2016 04 15; 76(8):2197-205. . View in PubMed
  • Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group J Clin Oncol. 2015 Dec 20; 33(36):4247-58. . View in PubMed
  • Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group Haematologica. 2015 Dec; 100(12):e496-500. . View in PubMed
  • Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children’s Oncology Group Leukemia. 2015 Dec; 29(12):2424-6. . View in PubMed
  • The genomic landscape of juvenile myelomonocytic leukemia Nat Genet. 2015 Nov; 47(11):1326-1333. . View in PubMed
  • Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children’s Oncology Group Pediatr Blood Cancer. 2015 Oct; 62(10):1775-81. . View in PubMed
  • Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus Open Forum Infect Dis. 2015 Sep; 2(3):ofv101. . View in PubMed
  • Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group Clin Cancer Res. 2015 Jul 15; 21(14):3187-95. . View in PubMed
  • Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children’s Oncology Group Cancer Genet. 2015 Jul-Aug; 208(7-8):408-13. . View in PubMed
  • Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children’s Oncology Group Pediatr Blood Cancer. 2015 Jul; 62(7):1184-9. . View in PubMed
  • Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2015 Apr; 62(4):629-36. . View in PubMed
  • Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia Blood. 2015 Jan 15; 125(3):516-24. . View in PubMed
  • High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group J Hematol Oncol. 2015 10 20; 8:115. . View in PubMed
  • Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children’s Oncology Group PLoS One. 2015; 10(4):e0125290. . View in PubMed
  • Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group PLoS One. 2015; 10(11):e0143480. . View in PubMed
  • High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group Leuk Lymphoma. 2014 Dec; 55(12):2817-21. . View in PubMed
  • NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report Blood. 2014 Oct 09; 124(15):2400-7. . View in PubMed
  • A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60. . View in PubMed
  • Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531 J Clin Oncol. 2014 Sep 20; 32(27):3021-32. . View in PubMed
  • AAML0523: a report from the Children’s Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia Cancer. 2014 Aug 15; 120(16):2482-9. . View in PubMed
  • Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children’s Oncology Group Br J Haematol. 2014 Jul; 166(2):254-259. . View in PubMed
  • BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2014 Apr; 61(4):647-52. . View in PubMed
  • Reducing decision errors in the paired comparison of the diagnostic accuracy of screening tests with Gaussian outcomes BMC Med Res Methodol. 2014 Mar 05; 14:37. . View in PubMed
  • Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation Pediatr Blood Cancer. 2014 Feb; 61(2):269-75. . View in PubMed
  • Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children’s Oncology Group Acta Haematol. 2014; 131(3):167-9. . View in PubMed
  • The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children’s Oncology Group Pediatr Blood Cancer. 2014 Jan; 61(1):81-8. . View in PubMed
  • Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children’s Oncology Group Cancer. 2013 Dec 01; 119(23):4162-9. . View in PubMed
  • NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern Leukemia. 2013 Dec; 27(12):2280-8. . View in PubMed
  • Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2013 Dec; 60(12):2073-8. . View in PubMed
  • Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials Cancer. 2013 Dec 01; 119(23):4170-9. . View in PubMed
  • Accuracy of a home-based device for giving an early estimate of pregnancy duration compared with reference methodsFertil Steril. 2013 Dec; 100(6):1635-41. e1. . View in PubMed
  • Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group Blood. 2013 Oct 10; 122(15):2704-13. . View in PubMed
  • High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children’s oncology group Br J Haematol. 2013 Sep; 162(5):670-7. . View in PubMed
  • Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children’s Oncology Group Am J Hematol. 2013 Aug; 88(8):694-702. . View in PubMed
  • Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children’s Oncology Group Br J Haematol. 2013 Jul; 162(2):250-62. . View in PubMed
  • Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children’s Oncology Group Pediatr Blood Cancer. 2013 Jul; 60(7):1141-7. . View in PubMed
  • Children’s Oncology Group’s 2013 blueprint for research: acute myeloid leukemia Pediatr Blood Cancer. 2013 Jun; 60(6):964-71. . View in PubMed
  • Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children’s Oncology Group Blood. 2013 May 02; 121(18):3573-7. . View in PubMed
  • Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis Br J Haematol. 2013 Apr; 161(2):192-203. . View in PubMed
  • Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy Clin Cancer Res. 2013 Mar 15; 19(6):1620-7. . View in PubMed
  • Generalization of Youden index for multiple-class classification problems applied to the assessment of externally validated cognition in Parkinson disease screening Stat Med. 2013 Mar 15; 32(6):995-1003. . View in PubMed
  • FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children’s Oncology Group report Blood. 2013 Feb 14; 121(7):1083-93. . View in PubMed
  • High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group Leuk Lymphoma. 2013 Jan; 54(1):202-4. . View in PubMed
  • Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group Haematologica. 2012 Nov; 97(11):1770-3. . View in PubMed
  • Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML Pediatr Blood Cancer. 2012 Nov; 59(5):922-4. . View in PubMed
  • Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children’s Oncology Group trial A2971: a report from the Children’s Oncology Group Cancer. 2012 Oct 01; 118(19):4806-14. . View in PubMed
  • Extending induced ROC methodology to the functional context Biostatistics. 2012 Sep; 13(4):594-608. . View in PubMed
  • Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group Blood. 2012 Aug 23; 120(8):1581-8. . View in PubMed
  • Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children’s Oncology Group Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:37-43. . View in PubMed
  • Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML Blood. 2012 Apr 19; 119(16):3705-11. . View in PubMed
  • Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2012 Apr; 58(4):519-24. . View in PubMed
  • Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study Br J Haematol. 2012 Mar; 156(5):649-55. . View in PubMed
  • AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group Cancer. 2012 Feb 01; 118(3):761-9. . View in PubMed
  • Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children’s Oncology Group J Pediatr Hematol Oncol. 2012 Jan; 34(1):e30-5. . View in PubMed
  • Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy Leuk Res. 2012 Jan; 36(1):29-31. . View in PubMed
  • Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971 Blood. 2011 Dec 22; 118(26):6752-9; quiz 6996. . View in PubMed
  • A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children’s Oncology Group study (AAML0121) Pediatr Blood Cancer. 2011 Dec 15; 57(7):1230-2. . View in PubMed
  • Nonparametric Bayesian estimation of the three-way receiver operating characteristic surface Biom J. 2011 Nov; 53(6):1011-24. . View in PubMed
  • Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children’s Oncology Group and SWOG Blood. 2011 Oct 27; 118(17):4561-6. . View in PubMed
  • Soluble interleukin-2 receptor a activation in a Children’s Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia Pediatr Blood Cancer. 2011 Sep; 57(3):398-405. . View in PubMed
  • Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2011 Aug; 57(2):204-9. . View in PubMed
  • Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2011 Jul 15; 57(1):56-62. . View in PubMed
  • Bias in estimating accuracy of a binary screening test with differential disease verification Stat Med. 2011 Jul 10; 30(15):1852-64. . View in PubMed
  • Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia Blood. 2011 Jun 30; 117(26):7007-13. . View in PubMed
  • Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study Blood. 2011 Jun 30; 117(26):7102-11. . View in PubMed
  • Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children’s Oncology Group Leukemia. 2011 Jun; 25(6):1039-42. . View in PubMed
  • Immediate vsdelayed post-abortal copper T 380A IUD insertion in cases over 12 weeks of gestation. Contraception. 2011 Jun; 83(6):522-7. . View in PubMed
  • Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents Clin Trials. 2011 Jun; 8(3):247-59. . View in PubMed
  • Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor Blood. 2011 May 26; 117(21):5701-9. . View in PubMed
  • Adequacy of visual inspection with acetic acid in women of advancing age Int J Gynaecol Obstet. 2011 Apr; 113(1):68-71. . View in PubMed
  • WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children’s oncology group J Clin Oncol. 2011 Feb 20; 29(6):704-11. . View in PubMed
  • Accuracy and cut-off point selection in three-class classification problems using a generalization of the Youden index Stat Med. 2010 Dec 10; 29(28):2946-55. . View in PubMed
  • Cytology versus visual inspection with acetic acid among women treated previously with cryotherapy in a low-resource setting Int J Gynaecol Obstet. 2010 Dec; 111(3):249-52. . View in PubMed
  • The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children’s Oncology Group study Pediatr Blood Cancer. 2010 Sep; 55(3):414-20. . View in PubMed
  • Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group Blood. 2010 Aug 05; 116(5):702-10. . View in PubMed
  • MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2010 Aug; 55(2):248-53. . View in PubMed
  • High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children’s oncology group J Clin Oncol. 2010 Jun 10; 28(17):2831-8. . View in PubMed
  • Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study Leukemia. 2010 May; 24(5):909-13. . View in PubMed
  • Diagnostic reproducibility of cervical intraepithelial neoplasia 3 and atrophy in menopausal women on hematoxylin and eosin, Ki-67, and p16 stained slides J Low Genit Tract Dis. 2010 Apr; 14(2):108-12. . View in PubMed
  • Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML Blood. 2010 Mar 25; 115(12):2372-9. . View in PubMed
  • Estimates of sensitivity and specificity can be biased when reporting the results of the second test in a screening trial conducted in series BMC Med Res Methodol. 2010 Jan 11; 10:3. . View in PubMed
  • Digital assessment of the reproductive tract versus colposcopy for directing biopsies in women with abnormal Pap smears J Low Genit Tract Dis. 2010 Jan; 14(1):5-10. . View in PubMed
  • WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2009 Dec; 53(6):1136-9. . View in PubMed
  • Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129 Pediatr Blood Cancer. 2009 Dec; 53(6):1005-10. . View in PubMed
  • A receiver operating characteristic analysis approach for the assessment of the separation of female Mediterranean fruit fly (Diptera: Tephritidae) oviposition distributions J Econ Entomol. 2009 Oct; 102(5):1985-91. . View in PubMed
  • Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study Blood. 2009 Sep 17; 114(12):2489-96. . View in PubMed
  • Effect of tidal volume in children with acute hypoxemic respiratory failure Intensive Care Med. 2009 Aug; 35(8):1428-37. . View in PubMed
  • Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group Blood. 2009 Jun 25; 113(26):6558-66. . View in PubMed
  • Comparing accuracy in an unpaired post-market device study with incomplete disease assessment Biom J. 2009 Jun; 51(3):491-503. . View in PubMed
  • Adolescent comprehension of emergency contraception in New York City Obstet Gynecol. 2009 Apr; 113(4):840-844. . View in PubMed
  • A comparison of tests for restricted orderings in the three-class case Stat Med. 2009 Mar 30; 28(7):1144-58. . View in PubMed
  • Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia Cancer. 2009 Mar 01; 115(5):1100-8. . View in PubMed
  • Disseminated intravascular coagulation score is associated with mortality for children with shock Intensive Care Med. 2009 Feb; 35(2):327-33. . View in PubMed
  • Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test Stat Biopharm Res. 2009 Feb 01; 1(1):18-25. . View in PubMed
  • Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia Br J Haematol. 2009 Feb; 144(3):388-94. . View in PubMed
  • Bias in trials comparing paired continuous tests can cause researchers to choose the wrong screening modality BMC Med Res Methodol. 2009 Jan 20; 9:4. . View in PubMed
  • Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children’s Oncology Group J Clin Oncol. 2008 Dec 10; 26(35):5797-801. . View in PubMed
  • Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children’s Oncology Group Pediatr Blood Cancer. 2008 Dec; 51(6):784-6. . View in PubMed
  • FAS promoter polymorphism: outcome of childhood acute myeloid leukemiaA children’s oncology group report. Clin Cancer Res. 2008 Dec 01; 14(23):7896-9. . View in PubMed
  • DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update Mol Cancer. 2008 Oct 23; 7:81. . View in PubMed
  • Structural and numerical variation of FLT3/ITD in pediatric AML Blood. 2008 May 15; 111(10):4930-3. . View in PubMed
  • Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group J Clin Oncol. 2008 May 10; 26(14):2390-3295. . View in PubMed
  • A modified sign test for comparing paired ROC curves Biostatistics. 2008 Apr; 9(2):364-72. . View in PubMed
  • Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group Blood. 2008 Feb 01; 111(3):1044-53. . View in PubMed
  • The MonoPrep Pap test for the detection of cervical cancer and its precursorsPart I: results of a multicenter clinical trial. Am J Clin Pathol. 2008 Feb; 129(2):193-201. . View in PubMed
  • DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children’s Oncology Group Leukemia. 2008 Feb; 22(2):265-72. . View in PubMed
  • Outcomes in childhood AML in the absence of transplantation in first remission–Children’s Cancer Group (CCG) studies 2891 and CCG 213 Pediatr Blood Cancer. 2008 Jan; 50(1):9-16. . View in PubMed
  • Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia Blood. 2007 Nov 15; 110(10):3532-9. . View in PubMed
  • Autologous bone marrow transplantation for children with AML in first remission Bone Marrow Transplant. 2007 Aug; 40(4):313-8. . View in PubMed
  • The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood. 2007 Aug 01; 110(3):979-85. . View in PubMed
  • Comparison of ROC umbrella volumes with an application to the assessment of lung cancer diagnostic markers Biom J. 2007 Aug; 49(5):654-64. . View in PubMed
  • Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children’s Oncology Group Pediatr Blood Cancer. 2007 Jul; 49(1):17-22. . View in PubMed
  • ROC graphs for assessing the ability of a diagnostic marker to detect three disease classes with an umbrella ordering Biometrics. 2007 Jun; 63(2):603-9. . View in PubMed
  • Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study Blood. 2007 Jun 01; 109(11):4641-7. . View in PubMed
  • Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children’s Oncology Group J Clin Oncol. 2007 May 20; 25(15):2070-7. . View in PubMed
  • Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children’s Oncology Group, studies CCG-2891 and CCG-2961 Blood. 2007 Mar 15; 109(6):2314-21. . View in PubMed
  • Statistical methods for evaluating DNA methylation as a marker for early detection or prognosis Dis Markers. 2007; 23(1-2):113-20. . View in PubMed
  • Development and evaluation of classifiers Methods Mol Biol. 2007; 404:89-116. . View in PubMed
  • Clinical implications of FLT3 mutations in pediatric AML Blood. 2006 Dec 01; 108(12):3654-61. . View in PubMed
  • FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia Blood. 2006 Oct 15; 108(8):2764-9. . View in PubMed
  • Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children’s Oncology Group Blood. 2006 Jul 01; 108(1):74-80. . View in PubMed
  • Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML Blood. 2006 Jul 01; 108(1):400; author reply 400-1. . View in PubMed
  • A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies Leukemia. 2006 Jul; 20(7):1295-7. . View in PubMed
  • A novel design for estimating relative accuracy of screening tests when complete disease verification is not feasible Biometrics. 2006 Jun; 62(2):605-12. . View in PubMed
  • Using the ROC curve for gauging treatment effect in clinical trials Stat Med. 2006 Feb 28; 25(4):575-90. . View in PubMed
  • XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children’s Oncology Group report Blood. 2006 Jan 01; 107(1):39-45. . View in PubMed
  • Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia J Clin Oncol. 2005 Dec 20; 23(36):9172-8. . View in PubMed
  • Standards for reporting prognostic tumor marker studies J Clin Oncol. 2005 Dec 20; 23(36):9053-4. . View in PubMed
  • Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891 Leukemia. 2005 Dec; 19(12):2054-62. . View in PubMed
  • Postremission therapy for children with acute myeloid leukemia: the children’s cancer group experience in the transplant era Leukemia. 2005 Jun; 19(6):965-70. . View in PubMed
  • Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests Stat Med. 2005 Feb 15; 24(3):403-17. . View in PubMed
  • Mortality in overweight and underweight children with acute myeloid leukemia JAMA. 2005 Jan 12; 293(2):203-11. . View in PubMed
  • Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia Blood. 2004 Nov 15; 104(10):3058-63. . View in PubMed
  • PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children’s Cancer Group Leukemia. 2004 Nov; 18(11):1831-4. . View in PubMed
  • Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition Blood. 2004 Sep 15; 104(6):1841-9. . View in PubMed
  • Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival Blood. 2004 May 15; 103(10):3655-61. . View in PubMed
  • Small sample estimation of relative accuracy for binary screening tests Stat Med. 2004 Jan 15; 23(1):21-34. . View in PubMed
  • Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children’s Cancer Group Study 2941 J Clin Oncol. 2004 Jan 01; 22(1):150-6. . View in PubMed
  • Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children’s Cancer Group J Pediatr Hematol Oncol. 2003 Oct; 25(10):760-8. . View in PubMed
  • Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891 J Clin Oncol. 2003 Sep 15; 21(18):3415-22. . View in PubMed
  • Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia Blood. 2003 Aug 15; 102(4):1474-9. . View in PubMed
  • The effects of intraoral splints on the masticatory system of pigs J Oral Rehabil. 2003 Aug; 30(8):823-31. . View in PubMed
  • Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children’s Cancer Group Study 2951 J Clin Oncol. 2003 Aug 01; 21(15):2940-7. . View in PubMed
  • Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children’s Cancer Group J Pediatr Hematol Oncol. 2003 Aug; 25(8):594-600. . View in PubMed
  • Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children’s Cancer Group study of 252 patients with acute myeloid leukemia Blood. 2003 May 01; 101(9):3398-406. . View in PubMed
  • Estimating disease prevalence in two-phase studies Biostatistics. 2003 Apr; 4(2):313-26. . View in PubMed
  • Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children’s Cancer Group J Pediatr Hematol Oncol. 2002 Nov; 24(8):627-35. . View in PubMed
  • Distribution-free ROC analysis using binary regression techniques Biostatistics. 2002 Sep; 3(3):421-32. . View in PubMed
  • Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? –an American view. Br J Haematol. 2002 Aug; 118(2):378-84.. View in PubMed
  • Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation Blood. 2002 Jul 15; 100(2):427-34. . View in PubMed
  • Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children’s Cancer Group Study 213 Leukemia. 2002 Apr; 16(4):601-7. . View in PubMed
  • Sample size calculations for comparative studies of medical tests for detecting presence of disease Stat Med. 2002 Mar 30; 21(6):835-52. . View in PubMed
  • Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children’s Cancer Group J Clin Oncol. 2002 Jan 15; 20(2):434-40. . View in PubMed
  • Comparing disease screening tests when true disease status is ascertained only for screen positives Biostatistics. 2001 Sep; 2(3):249-60. . View in PubMed
  • Effects of intraoral splint wear on proteoglycans in the temporomandibular joint disc Arch Biochem Biophys. 2000 Jul 01; 379(1):64-70. . View in PubMed
  • Comparisons of predictive values of binary medical diagnostic tests for paired designs Biometrics. 2000 Jun; 56(2):345-51. . View in PubMed
  • Using a combination of reference tests to assess the accuracy of a new diagnostic test Stat Med. 1999 Nov 30; 18(22):2987-3003. . View in PubMed
  • Evaluation of friction during sliding tooth movement in various bracket-arch wire combinations Am J Orthod Dentofacial Orthop. 1999 Sep; 116(3):336-45. . View in PubMed
  • Are dental anomalies risk factors for apical root resorption in orthodontic patients? Am J Orthod Dentofacial Orthop. 1999 Aug; 116(2):187-95.. View in PubMed
  • Building community for the long-term: an intergenerational commitment Gerontologist. 1999 Apr; 39(2):235-8. . View in PubMed